Denali Therapeutics Inc. Operating Income
Denali Therapeutics Inc. (DNLI) reported Operating Income of -$130.54 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- Denali Therapeutics Inc. operating income (loss) for the quarter ending 2026-06-30 was -$130.54M.
- Denali Therapeutics Inc. operating income (loss) for the quarter ending 2026-03-31 was -$137.36M.
- Denali Therapeutics Inc. operating income (loss) for the quarter ending 2025-12-31 was -$137.37M.
- Denali Therapeutics Inc. operating income (loss) for the quarter ending 2025-09-30 was -$137.43M.
- Denali Therapeutics Inc. operating income (loss) for fiscal 2025 was -$555.34M.
- Denali Therapeutics Inc. operating income (loss) for fiscal 2024 was -$487.34M.
- Denali Therapeutics Inc. operating income (loss) for fiscal 2023 was -$196.70M.
- Denali Therapeutics Inc. operating income (loss) for fiscal 2022 was -$340.74M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$130.54M 10-Q · filed 2026-08-06 | -$267.90M 10-Q · filed 2026-08-06 | -$405.26M derived: sum of 3 quarters · filed 2026-08-06 | -$542.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$137.36M 10-Q · filed 2026-05-07 | -$274.72M derived: sum of 2 quarters · filed 2026-05-07 | -$412.16M derived: sum of 3 quarters · filed 2026-05-07 | -$547.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$137.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$274.80M derived: sum of 2 quarters · filed 2026-02-26 | -$409.76M derived: sum of 3 quarters · filed 2026-08-06 | -$555.34M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$137.43M 10-Q · filed 2025-11-06 | -$272.40M derived: sum of 2 quarters · filed 2026-08-06 | -$417.98M 10-Q · filed 2025-11-06 | -$547.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$134.96M 10-Q · filed 2026-08-06 | -$280.54M 10-Q · filed 2026-08-06 | -$410.39M derived: sum of 3 quarters · filed 2026-08-06 | -$533.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$145.58M 10-Q · filed 2026-05-07 | -$275.43M derived: sum of 2 quarters · filed 2026-05-07 | -$398.61M derived: sum of 3 quarters · filed 2026-05-07 | -$515.21M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$129.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$253.03M derived: sum of 2 quarters · filed 2026-02-26 | -$369.63M derived: sum of 3 quarters · filed 2026-02-26 | -$487.34M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$123.19M 10-Q · filed 2025-11-06 | -$239.78M derived: sum of 2 quarters · filed 2025-11-06 | -$357.50M 10-Q · filed 2025-11-06 | -$490.07M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$116.59M 10-Q · filed 2025-08-11 | -$234.31M 10-Q · filed 2025-08-11 | -$366.88M derived: sum of 3 quarters · filed 2026-02-26 | -$480.68M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$117.72M 10-Q · filed 2025-05-06 | -$250.29M derived: sum of 2 quarters · filed 2026-02-26 | -$364.08M derived: sum of 3 quarters · filed 2026-02-26 | -$193.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$132.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$246.37M derived: sum of 2 quarters · filed 2026-02-26 | -$75.88M derived: sum of 3 quarters · filed 2026-02-26 | -$196.70M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$113.80M 10-Q · filed 2024-11-06 | $56.69M derived: sum of 2 quarters · filed 2024-11-06 | -$64.13M 10-Q · filed 2024-11-06 | -$169.47M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $170.48M 10-Q · filed 2024-08-01 | $49.67M 10-Q · filed 2024-08-01 | -$55.68M derived: sum of 3 quarters · filed 2025-02-27 | -$163.16M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$120.81M 10-Q · filed 2024-05-07 | -$226.16M derived: sum of 2 quarters · filed 2025-02-27 | -$333.64M derived: sum of 3 quarters · filed 2025-02-27 | -$395.06M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$105.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$212.83M derived: sum of 2 quarters · filed 2025-02-27 | -$274.25M derived: sum of 3 quarters · filed 2025-02-27 | -$340.74M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$107.49M 10-Q · filed 2023-11-07 | -$168.90M derived: sum of 2 quarters · filed 2023-11-07 | -$235.40M 10-Q · filed 2023-11-07 | -$312.52M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$61.42M 10-Q · filed 2023-08-08 | -$127.91M 10-Q · filed 2023-08-08 | -$205.03M derived: sum of 3 quarters · filed 2024-02-28 | -$290.63M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$66.50M 10-Q · filed 2023-05-08 | -$143.62M derived: sum of 2 quarters · filed 2024-02-28 | -$229.21M derived: sum of 3 quarters · filed 2024-02-28 | -$291.03M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$77.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$162.71M derived: sum of 2 quarters · filed 2024-02-28 | -$224.53M derived: sum of 3 quarters · filed 2024-02-28 | -$295.75M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$85.59M 10-Q · filed 2022-11-03 | -$147.41M derived: sum of 2 quarters · filed 2022-11-03 | -$218.63M 10-Q · filed 2022-11-03 | $25.45M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$61.82M 10-Q · filed 2022-08-08 | -$133.04M 10-Q · filed 2022-08-08 | $111.04M derived: sum of 3 quarters · filed 2023-02-27 | $50.92M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$71.22M 10-Q · filed 2022-05-05 | $172.86M derived: sum of 2 quarters · filed 2023-02-27 | $112.74M derived: sum of 3 quarters · filed 2023-02-27 | $51.47M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $244.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $183.96M derived: sum of 2 quarters · filed 2023-02-27 | $122.69M derived: sum of 3 quarters · filed 2023-02-27 | $62.72M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$60.12M 10-Q · filed 2021-11-04 | -$121.39M derived: sum of 2 quarters · filed 2021-11-04 | -$181.36M 10-Q · filed 2021-11-04 | -$239.12M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$61.28M 10-Q · filed 2021-08-04 | -$121.24M 10-Q · filed 2021-08-04 | -$179.00M derived: sum of 3 quarters · filed 2021-08-04 | -$229.16M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | -$59.97M 10-Q · filed 2021-05-05 | -$117.72M derived: sum of 2 quarters · filed 2021-05-05 | -$167.88M derived: sum of 3 quarters · filed 2021-05-05 | -$230.64M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | -$57.76M 10-K · filed 2020-02-27 | -$107.91M derived: sum of 2 quarters · filed 2020-11-05 | -$170.68M derived: sum of 3 quarters · filed 2020-11-05 | -$213.18M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$50.16M 10-Q · filed 2020-11-05 | -$112.92M derived: sum of 2 quarters · filed 2020-11-05 | -$155.43M 10-Q · filed 2020-11-05 | -$80.70M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | -$62.76M 10-Q · filed 2020-08-07 | -$105.27M 10-Q · filed 2020-08-07 | -$30.55M derived: sum of 3 quarters · filed 2020-08-07 | -$68.51M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | -$42.51M 10-Q · filed 2020-05-07 | $32.21M derived: sum of 2 quarters · filed 2020-05-07 | -$5.75M derived: sum of 3 quarters · filed 2020-05-07 | -$63.13M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $74.72M 10-K · filed 2020-02-27 | $36.76M derived: sum of 2 quarters · filed 2020-02-27 | -$20.62M derived: sum of 3 quarters · filed 2020-02-27 | -$46.37M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$37.96M 10-K · filed 2020-02-27 | -$95.35M derived: sum of 2 quarters · filed 2020-02-27 | -$121.09M 10-Q · filed 2019-11-06 | -$144.63M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$57.38M 10-K · filed 2020-02-27 | -$83.13M 10-Q · filed 2019-08-06 | -$106.67M derived: sum of 3 quarters · filed 2020-02-27 | -$128.96M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$25.75M 10-K · filed 2020-02-27 | -$49.29M derived: sum of 2 quarters · filed 2020-02-27 | -$71.58M derived: sum of 3 quarters · filed 2020-02-27 | -$94.14M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | -$23.54M 10-K · filed 2019-03-12 | -$45.83M derived: sum of 2 quarters · filed 2019-03-12 | -$68.40M derived: sum of 3 quarters · filed 2019-03-12 | -$90.14M 10-K · filed 2020-02-27 |
| 2017-09-30 | -$22.29M 10-K · filed 2019-03-12 | -$44.86M derived: sum of 2 quarters · filed 2019-03-12 | -$66.60M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | -$22.57M 10-K · filed 2019-03-12 | -$44.31M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | -$21.74M 10-K · filed 2019-03-12 | |||
| 2016-12-31 | -$87.43M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |